2. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan W, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-52.

3. Peuskens J on behalf of the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166:712-26.

4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Third edition revised (DSM-III-R). Washington, DC: 1987.

5. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-76.

6. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health; 1976 DHEW publication no. (ADM) 76-338.

7. Chouinard G, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980; 7:233-48.

8. Livington MG. Risperidone. Lancet 1994; 343:457-60.

9. Lindström E, Eriksson B, Hellgren A, von Knorring L, Eberhard G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17:402-12.

10. Binder RL, Levy R. Extrapyramidal reactions in Asians. Am J Psychiatry 1981; 138:1241-4.